Association of interleukin‐18 polymorphisms and plasma level with the outcome of chronic HCV infection

Bouzgarrou, Nadia; Hassen, Elham; Schvoerer, Évelyne; Stoll‐Keller, Françoise; Bahri, Olfa; Gabbouj, Sallouha; Cheikh, Imed; Màamouri, N.; Mammi, N.; Saffar, H.; Trabelsi, Amel; Triki, Henda; Chouchane, Lotfi

doi:10.1002/jmv.21079

Cited by 41 publications

(36 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Accordingly, the C allele was the most common allele in both patients and controls. These fi ndings are consistent with previous studies that reported no differences in -607C/A genotype distributions and allele frequencies between patients and controls 26,27 .…”

Section: Relationships Between Treatment Response and The Il-18 Gene supporting

confidence: 93%

See 1 more Smart Citation

Impact of the IL-18 gene polymorphism in response to antiviral therapy in chronic HCV genotype 4 patients

Mandour

Nemr

Kishk

et al. 2014

Rev. Soc. Bras. Med. Trop.

View full text Add to dashboard Cite

Introduction: Interleukin (IL)-18 is a well-known major proinfl ammatory cytokine with broad biological effects. The major immunomodulatory functions of IL-18 include enhancing T cell and natural killer cell cytotoxicity. Serum levels of this cytokine were shown to increase in chronic hepatitis C patients compared to non-infected healthy people. An association between IL-18 gene promoter polymorphisms and pegylated interferon (PEG-IFN) and ribavirin treatment outcomes has been reported for individuals with chronic hepatitis C virus genotype 1 (HCV-1). In this study, HCV genotype 4 (HCV-4) patients were assessed for IL-18 gene polymorphisms and treatment outcomes or severity of liver disease because data concerning the impact of IL-18 gene polymorphisms on patients with HCV-4 infections are limited. Methods: This study included 123 chronic HCV-4 Egyptian patients and 123 apparently healthy volunteer blood donors who served as a control group. HCV genotyping was performed using the line probe assay. IL-18 genotyping was performed using the TaqMan Real-Time PCR method in all 246 patient and control samples. Results: In our study, all patients had HCV-4. IL-18 gene single nucleotide polymorphism (SNP) (-607C/A) genotype distributions and allele frequencies did not differ between HCV patients and normal healthy subjects or between patient groups when compared according to the therapeutic response. Moreover, the presence of an IL-18 SNP was not associated with histological disease severity. We conclude that the presence of the IL-18 SNP rs1946518 does not affect the outcome of chronic HCV-4 treatment in Egyptian patients. Conclusions: The IL-18 SNP rs1946518 does not affect response to treatment in chronic HCV-4 patients.

show abstract

Section: Relationships Between Treatment Response and The Il-18 Gene supporting

confidence: 93%

“…Bouzgarrou et al and colleagues 26 studied the correlations among serum IL-18, HCV infection outcomes and IL-18 gene promoter SNPs (-137G/C and -607C/A). A comparison of different stages and severities of HCV infection and IL-18 levels revealed a positive correlation with disease progression.…”

Section: Relationships Between Treatment Response and The Il-18 Gene mentioning

confidence: 99%

Impact of the IL-18 gene polymorphism in response to antiviral therapy in chronic HCV genotype 4 patients

Mandour

Nemr

Kishk

et al. 2014

Rev. Soc. Bras. Med. Trop.

View full text Add to dashboard Cite

show abstract

“…Similarly, the involvement of IL-18, well known for its contribution to the stimulation of Th1 response and the induction of inflammatory cytokines, has already been thoroughly investigated [21,22]. Several studies including ours have reported a positive correlation between IL-18 level and hepatitis C severity [10,[23][24][25][26].…”

Section: Introductionmentioning

confidence: 84%

“…The IL-18 -607C/A, IL-18 -137G/C, IFN-c ?874T/A and IL-10 -1082G/A genotypes were determined as previously described [25,34].…”

Section: Genotypingmentioning

confidence: 99%

“…Therefore, the majority of studies related to associations between polymorphisms within immune genes and hepatitis C outcome have focused on cytokine genes, and particularly on those participating to Th1 and/or Th2 immune responses [28][29][30][31][32][33]. We have previously reported association studies of the IL-18, IFN-c, and IL-10 single nucleotide polymorphisms with chronic hepatitis C outcome [25,34]. In accordance with our findings, some significant associations with regard to IL-18 and IFN-c polymorphisms have been observed [30,35].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Combined effect of pro- and anti-inflammatory cytokine gene polymorphisms on susceptibility to liver cirrhosis in Tunisian HCV-infected patients

et al. 2011

View full text Add to dashboard Cite

Association of genetic variants in the interleukin‐18 gene promoter with risk of hepatocellular carcinoma and metastasis in patients with hepatitis C virus infection

2018

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is a primary malignancy of the liver, characterized by high vascularization and rapid tumor progression. The current case-control study aimed to analyze the influence of -607C/A and -137G/C polymorphisms in the interleukin-18 (IL-18) promoter on the risk of HCC occurrence and metastasis in Egyptian patients infected with hepatitis C virus (HCV). Both genetic variations were genotyped in 279 subjects including HCV patients with and without HCC and unrelated healthy subjects, using the allele-specific polymerase chain reaction (AS-PCR) method. The relationship between clinico-laboratory parameters including serum level of alpha-fetoprotein (AFP) and these polymorphisms was evaluated in HCC patients. The IL-18-607A allele and AA genotype were significantly related to a higher risk of developing HCC when comparing patients with HCC and controls, and were significantly related to a higher risk of metastasis when comparing metastatic and nonmetastatic groups in the Egyptian patients. In contrast, the IL18-137C allele and GC genotype were significantly related to a lower risk of developing HCC when comparing patients with HCC and controls, and HCV patients with and without HCC. A significant association was found between multinodular HCC and IL-18-607AA genotype, while, uninodular HCC was significantly associated with IL-18-137GG genotype. In addition, IL18-607AA and -137GG genotypes showed significant association with higher level of serum AFP. The detection of polymorphisms in the IL-18 promoter, in a combination with an evaluation of level of serum AFP, could be used as a molecular biomarker in the early diagnosis of HCC, which would aid the early management of the disease, thus decreasing the rate of mortality of this disease. © 2018 IUBMB Life, 70(2):165-174, 2018.

show abstract

Association of interleukin‐18 polymorphisms and plasma level with the outcome of chronic HCV infection

Cited by 41 publications

References 68 publications

Impact of the IL-18 gene polymorphism in response to antiviral therapy in chronic HCV genotype 4 patients

Impact of the IL-18 gene polymorphism in response to antiviral therapy in chronic HCV genotype 4 patients

Combined effect of pro- and anti-inflammatory cytokine gene polymorphisms on susceptibility to liver cirrhosis in Tunisian HCV-infected patients

Association of genetic variants in the interleukin‐18 gene promoter with risk of hepatocellular carcinoma and metastasis in patients with hepatitis C virus infection

Contact Info

Product

Resources

About